Analyzing risk factors for lung transplant complications
Official title: Clinical Risk Factors for Primary Graft Dysfunction
Run by University of Pennsylvania · NCT00552357 · Data updated 2026-11-12
This study is trying to see if certain chemicals in the blood can help predict the risk of serious complications after lung transplants.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 13 Years to 68 Years |
| Sex | All |
| Enrollment | 1150 (estimated) |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | December 2007 |
| Main results expected | June 2027 |
| Study ends | June 2027 |
| Registry record updated | July 22, 2026 |
| Trial ID | NCT00552357 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals scheduled for lung or combined heart and lung transplantation.
✕Probably not a fit
Patients undergoing combined organ transplantation other than heart and lung transplantation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on primary graft dysfunction (PGD), a serious complication that can occur after lung transplantation. Researchers will analyze blood samples from patients undergoing lung or heart-lung transplants to identify if elevated levels of certain chemicals are linked to an increased risk of developing PGD. Blood samples will be collected before surgery, immediately after, and 24 hours post-surgery, alongside a review of medical records. The findings aim to improve understanding of PGD and potentially guide future transplant eligibility criteria.
Why it matters
Potential benefit: If successful, this study could help identify patients at higher risk for PGD, leading to better management strategies and improved outcomes after lung transplantation.
How similar studies have gone: While studies on PGD exist, this specific approach of analyzing blood markers for risk assessment is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Undergoing lung or combined heart and lung transplantation Exclusion Criteria: * Undergoing combined organ transplantation other than heart and lung transplantation
Where it's running
-
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Jason D. Christie, MD — University of Pennsylvania
- Study coordinator: E.J. Demissie, MSN
- Phone: 215-573-4767
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CCR5 immune blockade to prevent primary graft dysfunction after lung transplant
This trial will test whether the drug Maraviroc can prevent primary graft dysfunction in adults undergoing bilateral lung transplantation who have a PGD risk score greater than 50%.
-
Muscle health before and after lung transplant in adults
This study tests how respiratory and leg muscle health relates to physical function and recovery in adults awaiting and after lung transplantation.
-
Prediction score for death or lung transplant in emphysema caused by alpha-1 antitrypsin deficiency
This study tests a new prediction tool to identify people with emphysema due to alpha-1-antitrypsin deficiency who are at high risk of death or needing a lung transplant.
-
Long-term health of children born to mothers who had a solid organ transplant
This project will look for long-term heart, kidney, and immune system problems in people aged 16 and older who were born to mothers who had a kidney, liver, pancreas, heart, or lung transplant.
-
Temperature-controlled heart preservation system vs ice for primary graft dysfunction
This study tests whether using the Xo Port Organ Preservation System can reduce severe graft dysfunction after heart transplant compared with traditional ice storage in adult recipients.
-
Aerobic versus high-intensity interval exercise for people awaiting lung transplant
This trial tests whether short bursts of high-intensity interval training or longer moderate aerobic sessions better improve walking distance and daily function for people with interstitial lung disease who are on the lung transplant waiting list.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.